Payment overview · 2025
General Payments
$4,045.45
203 reported records · 34 companies
Healthcare provider profile · identity verified
Drew Ryan Uhrig, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BIRMINGHAM, AL · NPI 1578829834
Verified facts
What the public records show
CMS Open Payments records show Drew Ryan Uhrig, M.D. received $4,045.45 in general payments during 2025 across 203 reported records.
ABBVIE INC. accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gamunex-C, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ubrelvy by this doctor in 2024.
CATALYST PHARMACEUTICALS, INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FIRDAPSE as an associated drug or biological on 1474 records involving 920 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Firdapse by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Privigen by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $618.79 | 15.3% | 39 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $385.16 | 9.5% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $344.65 | 8.5% | 23 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $287.30 | 7.1% | 10 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $233.93 | 5.8% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $214.39 | 5.3% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $205.08 | 5.1% | 9 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $201.04 | 5.0% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $168.68 | 4.2% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $154.46 | 3.8% | 8 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $131.17 | 3.2% | 5 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $102.05 | 2.5% | 4 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $95.93 | 2.4% | 4 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $87.19 | 2.2% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $82.91 | 2.0% | 3 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$79.38 | 2.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $77.37 | 1.9% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $68.38 | 1.7% | 2 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $60.36 | 1.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $55.66 | 1.4% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $51.86 | 1.3% | 2 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $49.95 | 1.2% | 2 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $47.60 | 1.2% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $32.29 | 0.8% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $31.90 | 0.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$29.42 | 0.7% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.46 | 0.6% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$22.63 | 0.6% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.84 | 0.5% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $19.51 | 0.5% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $17.32 | 0.4% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.67 | 0.4% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $15.62 | 0.4% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.50 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,045.45 | 203 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $329.61 | 22 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $329.61 | 22 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $296.93 | 22 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $287.30 | 10 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $269.20 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $263.52 | 18 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $259.72 | 13 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $239.38 | 10 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $233.93 | 10 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $214.39 | 11 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $188.03 | 8 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $154.46 | 8 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $131.17 | 5 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $124.17 | 9 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $111.50 | 4 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc. | $102.05 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $95.93 | 4 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $77.37 | 4 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $68.38 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $68.38 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $68.38 | 2 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $60.36 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $55.66 | 3 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $49.95 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $44.57 | 3 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $44.57 | 3 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $44.51 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $39.79 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka Pharmaceutical Development & Commercialization, Inc. | $34.37 | 2 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $32.29 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $31.90 | 1 | 2025 |
Source payment records
|
|||||
| SOLITAIRE X Normalized: solitaire x |
Device | Medtronic, Inc. | $29.42 | 1 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $26.94 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $24.47 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| Dysport Normalized: dysport |
Drug | Ipsen Biopharmaceuticals, Inc | $19.84 | 1 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $15.62 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $4.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| CATALYST PHARMACEUTICALS, INC. Exact reporting entity; no affiliate inference |
2025 | FIRDAPSE open payments reported associated product |
CMS Open Payments — General Payments 1474 supporting records · 920 recipient NPIs · example record 1253216494 |
Firdapse · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 677 | 165 |
| Donepezil Hcl | Donepezil Hcl | 406 | 133 |
| Memantine Hcl | Memantine Hcl | 325 | 95 |
| Pregabalin | Pregabalin | 275 | 73 |
| Duloxetine Hcl | Duloxetine Hcl | 233 | 64 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 224 | 66 |
| Levetiracetam | Levetiracetam | 159 | 49 |
| Methocarbamol | Methocarbamol | 146 | 38 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 143 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 130 | 43 |
| Clonazepam | Clonazepam | 122 | 20 |
| Lacosamide | Lacosamide | 114 | 28 |
| Sumatriptan Succinate | Sumatriptan Succinate | 114 | 21 |
| Topiramate | Topiramate | 112 | 26 |
| Rizatriptan | Rizatriptan Benzoate | 109 | 38 |
| Primidone | Primidone | 107 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 97 | 26 |
| Prednisone | Prednisone | 92 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 21 |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 76 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 71 | 22 |
| Baclofen | Baclofen | 70 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 69 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 68 | 17 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 67 | 20 |
| Lamotrigine | Lamotrigine | 66 | 17 |
| Galantamine Er | Galantamine Hbr | 64 | 17 |
| Aimovig Autoinjector | Erenumab-Aooe | 59 | 13 |
| Oxcarbazepine | Oxcarbazepine | 58 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 56 | 17 |
| Ubrelvy | Ubrogepant | 55 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Sertraline Hcl | Sertraline Hcl | 50 | 17 |
| Mirtazapine | Mirtazapine | 49 | 11 |
| Azathioprine | Azathioprine | 48 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 16 |
| Buspirone Hcl | Buspirone Hcl | 47 | 11 |
| Lorazepam | Lorazepam | 45 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 41 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 40 | 15 |
| Emgality Pen | Galcanezumab-Gnlm | 40 | suppressed |
| Levetiracetam Er | Levetiracetam | 39 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 38 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 36 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 35 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 34 | suppressed |
| Diazepam | Diazepam | 33 | 11 |
| Memantine Hcl Er | Memantine Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 29 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 28 | suppressed |
| Lamotrigine Er | Lamotrigine | 27 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Qulipta | Atogepant | 27 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 26 | suppressed |
| Alprazolam | Alprazolam | 25 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 24 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 24 | suppressed |
| Rivastigmine | Rivastigmine | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 13 |
| Neupro | Rotigotine | 21 | suppressed |
| Zonisamide | Zonisamide | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Entacapone | Entacapone | 20 | suppressed |
| Nourianz | Istradefylline | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Carbamazepine Er | Carbamazepine | 19 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 18 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Meloxicam | Meloxicam | 14 | suppressed |
| Acetazolamide Er | Acetazolamide | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 13 | suppressed |
| Glatopa | Glatiramer Acetate | 13 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 13 | suppressed |
| Firdapse | Amifampridine Phosphate | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 12 | suppressed |
| Pyridostigmine Bromide Er | Pyridostigmine Bromide | 12 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,045.45 · 203 records | ABBVIE INC. | AMPYRA, AVONEX, BOTOX, Briviact, CREXONT, Dysport, EMGALITY, FYCOMPA, Gamunex-C, HYQVIA, Hizentra, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, LEQEMBI, Motpoly XR, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), Ocrevus, Ocrevus Zunovo, PANZYGA, QULIPTA, REXULTI, Radicava, Rystiggo, SOLITAIRE X, Symbravo, TREMFYA, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VUMERITY, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, Xeomin, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gamunex-C play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error